Apremilast

FACEMIL®

Apremilast 10 mg, 20 mg y 30 mg (Initiation Kit). Coated tablets. 
Apremilast 30 mg (Maintenance Kit). Coated tablets.


Pharmaceutical form

Coated tablets.


Therapeutical action

Selective immunosuppressant


Indications

Psoriatic Arthritis

FACEMIL® is indicated for the treatment of active Psoriatic Arthritis (PsA). 

Psoriasis:

FACEMIL® is indicated for the treatment of moderate to severe chronic plaque Psoriasis in adult patients who are candidates for phototherapy or systemic therapy.

Oral Ulcers Associated with Behçet’s Disease:
 
FACEMIL® is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
 

Dose and Administration

After an initial titration schedule, the recommended dose of FACEMIL® is 30 mg twice daily taken orally, morning and evening, approximately 12 hours apart, with no food restrictions. For further details, see information in the product leaflet. 


How supplied

FACEMIL®/ APREMILAST 10 mg, 20 mg y 30 mg (Initiation Kit): package containing 4 coated tables 10 mg + 4 coated tablets 20 mg + 19 coated tables 30 mg.

FACEMIL®/ APREMILAST 30 mg (Maintenance Kit): package containing 60 coated tablets.
 

Storage

Store in the original package at a temperature below 25°C.
 
 

Encarnación Ezcurra 365 Piso 3, C1107CLA, Buenos Aires, Argentina - Phone/Fax: 54 11 5787 2222